AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00611442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lubiprostone
Description: lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
Study NCT00611442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo gelcap, taken at noon the day prior to the colonoscopy
Study NCT04051710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study NCT04051710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study NCT04051710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study NCT02870075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fed exercise
Description: Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
Study NCT02870075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasted exercise
Description: Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
Study NCT01314170 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Susanna Implant
Description: device
Study NCT02264665 — intervention group
Intervention type: DRUG
Intervention: sunitinib
Description: sunitinib 37.5mg/d orally
Study NCT02264665 — intervention group
Intervention type: DRUG
Intervention: everolimus
Description: everolimus 10mg/d orally
Study NCT02264665 — intervention group
Intervention type: DRUG
Intervention: chemotherapies recommended in france
Description: depends on the chemotherapy prescribed (IV)
Study NCT02581956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
Study NCT02581956 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No walking exercise
Description: no exercise
Study NCT05989087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF
Description: Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
Study NCT04538235 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic Regional Analgesia
Description: In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
Study NCT02465788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleTouch
Description: Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
Study NCT01610440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: rehabilitation therapy plus human umbilical cord mesenchymal stem cells
Study NCT02545660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLF Image
Description: At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
Study NCT02545660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light Image
Description: At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
Study NCT03443830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
Study NCT02904824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose derived regenerative cells
Description: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
Study NCT02904824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: centrifuged autologous fat
Description: centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
Study NCT03700385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOWA Approach Endocardial Ablation System
Description: Endocardial ablation using the IOWA Approach Endocardial Ablation System
Study NCT01617252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow / Facial mask
Description: J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
Study NCT01853800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Study NCT01559922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of up to 2 study treatments administered 6 weeks apart
Study NCT01559922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artefill
Description: Administration of up to 2 study treatments administered 6 weeks apart
Study NCT04022421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: the drug will be taken by one group of the patients daily at a dose of 400mg
Study NCT01567787 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation for MPNST
Description: 30 CGE at 6 CGE/Fx
Study NCT01567787 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation for neurofibromas
Description: 25 CGE at 5 CGE/Fx
Study NCT04263714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise and resistance exercise
Study NCT02325349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)
Description: PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
Study NCT01630226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin Chemotherapy
Description: Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
Study NCT03389789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose solution + maternal holding
Description: Infant will receive both the oral glucose solution and the contact with the mother
Study NCT03389789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Infants will be breastfed
Study NCT03389789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose solution
Description: Infant will receive only oral glucose solution without contact with the mother
Study NCT03389789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral expressed breastmilk
Description: Infant will receive only oral expressed breast milk without contact with the mother
Study NCT01370928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus PCF-Y0014-L
Description: Screening colonoscopy with a prototype colonoscope
Study NCT01370928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscope
Description: Screening colonoscopy
Study NCT01560494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAC curriculum
Description: The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02150616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Study NCT02150616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Study NCT03082313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Intervention
Description: At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
Study NCT02909959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Study NCT02909959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Study NCT04332094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
Study NCT04332094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
Study NCT04332094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
Study NCT04332094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg / day v.o. for 3 days
Study NCT04332094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg / day v.o. for 3 days
Study NCT01752959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 0.1-0.3 micg/kg/min Remifentanil iv infusion
Study NCT01752959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: 500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
Study NCT03340909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
Study NCT03340909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 week starter kit followed by 1mg twice daily for 12 weeks.
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: Multi-daily dosing, range 3-9 mg daily for 25 days.
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline Placebo
Description: 1 week starter kit followed by 1 pill twice daily for 12 weeks.
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytisine Placebo
Description: Multi-daily dosing for 25 days.
Study NCT02797587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Placebo
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Study NCT00753545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Tablets Oral BID
Study NCT00753545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo bid
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control breakfast
Description: It consists of 350 ml of water at room temperature.
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control breakfast
Description: It consists of 350 ml of water at room temperature.
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
Study NCT02616276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
Study NCT00978588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Description: Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
Study NCT00978588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Description: Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
Study NCT02861456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Model of Care
Study NCT02861456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative Model of Care
Study NCT01788605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Study NCT03958773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve transfemoral Mitral valve system
Description: Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
Study NCT01727570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein (Immunocal®)
Description: The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL
Description: Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.